Explore our newest products
We are a world leader in pharmaceutical excipients, vaccine adjuvants and lipid delivery systems for human and veterinary applications.
Find out more information on our newest products:
Super Refined™ Poloxamer 188
Super Refined™ Poloxamer 188 is added to cell culture media to protect cells from shear stress caused by agitation in a bioreactor. Super Refined™ Poloxamer 188 has been optimised specifically for mammalian cell culture with tightly controlled impurity profiles and molecular weight, ensuring optimal cell culture performance and batch-to-batch consistency.
Sustainable Squalene
Introducing our Sustainable Squalene, produced using cutting-edge technology that centres on synthetic biology, our pharmaceutical-grade squalene has superior purity and carries the same squalene benefits as shark-derived squalene.
Sustainable saponins (2024)
As we look to become more nature positive, we’re proud to be able to offer our next-generation QS 21 and support global sustainability efforts. Our next-generation QS 21 is based on plant tissue culture, which makes the process more efficient and sustainably sourced.
Introducing Virodex™
We’re introducing our new range of detergents specifically designed to support the key steps in your biomanufacturing processes.
Introducing NatraPhos™, our highly purified, natural phospholipids:
4 items available
NatraPhos™ Soya PC100-C Pharma
NatraPhos™ Soya PC100-C is a highly purified soybean lecithin containing predominantly phosphatidylcholine.
NatraPhos™ PL95E Pharma
NatraPhos™ PL95E is a highly purified egg yolk lecithin containing predominantly phosphatidylcholine and a smaller amount of phosphatidylethanolamine.
NatraPhos™ Soya PC80-C Pharma
NatraPhos™ Soya PC80-C is a highly purified soybean lecithin containing predominantly phosphatidylcholine.
NatraPhos™ PL95EN Pharma
NatraPhos™ PL95EN is a highly purified egg yolk lecithin containing predominantly phosphatidylcholine and a smaller amount of phosphatidylethanolamine.
How we empower biologics delivery
Explore recent blogs:
The Nitrosamine challenge in pharmaceuticals
Since 2018 the risk of nitrosamine impurities in medicinal products has become a critical concern for pharmaceutical manufacturers and regulators alike
Gain insights from our experts...
Explore our poster: Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system. The success of mRNA vaccines during the COVID-19 pandemic has accelerated the...
Croda celebrates opening of expanded UK facility, bolstering global Super Refined™ capabilities
Croda International Plc (“Croda”), the company that uses smart science to create high-performance ingredients and pharmaceutical excipients that improve lives, celebrated the opening of its newly...